EFPIA disclosure
Disclosure of Boehringer Ingelheim affiliates in countries with EFPIA member associations and disclosures of transfers of value (ToVs) to HCPs and HCOs.
Search
COVID-19: EFPIA Industry Information
The EFPIA and its member companies and associations are committed to the global fight against the coronavirus pandemic. Click here to learn more.
Trust Through Transparency
Trust is a precious thing, and building trust takes hard work—especially in the healthcare sector. Click here to learn more about how we build trust.
Self certificate EFPIA Disclosure 2022 signed_10062022
Innovation Needs Transparency
At Boehringer Ingelheim, we prioritise the establishment and maintenance of public trust. Transparency is therefore a key pillar of our corporate culture.
Patient Organizations
Boehringer Ingelheim’s core principles and vision guide our work with patient organisations. Learn about how we collaborate with patient organisations.
COVID-19 IMI2–Call 21
CARE launched to accelerate therapy development against COVID-19 and future coronavirus threats.
What can the patient do?
Be aware and know your source.
Innovation Through Cooperation
Exchange of information between pharmaceutical manufacturers and healthcare professionals is essential for patients. Click here to learn more.
Ethics and Compliance
Find out about our ethical and compliance standards here. Access and view our Speak Up Policy, EFPIA disclosure, and Supplier Code of Conduct.
Ethical Business Practices
Suppliers shall conduct their business in an ethical manner and act with integrity. Click here to read the supplier code of conduct and learn more.